San Diego-dependent Viking Therapeutics marked itself as a serious competitor within the weight loss drug industry in February following revealing promising knowledge from the mid-stage demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when supplied for a weekly injection and in March the compa